SCHEMBL2128170

SCHEMBL2128170

COc1c(C(=O)Nc2ccc(N(C)S(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
LMNA P02545 5/20 0.42
ALDH1A1 P00352 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
USP2 O75604 1/20 0.42
MAPK1 P28482 4/20 0.41
RAB9A P51151 4/20 0.40
HTT P42858 1/20 0.40
ABL1 P00519 1/20 0.40
MAPT P10636 5/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
TP53 P04637 3/20 0.39
STAT3 P40763 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127583 0.90 CYP3A4 (0.50) CYP3A4LMNAALDH1A1MEN1KMT2A
SCHEMBL1542824 0.85 CYP3A4 (0.52) CYP3A4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL1542666 0.85 CYP3A4 (0.56) CYP3A4MEN1KMT2AKDM4EHTT
SCHEMBL1543035 0.84 CYP3A4 (0.61) CYP3A4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL1542683 0.82 CYP3A4 (0.61) CYP3A4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL1542202 0.80 CYP3A4 (0.60) CYP3A4LMNAALDH1A1MEN1KMT2A
SCHEMBL1542187 0.79 CYP3A4 (0.49) CYP3A4LMNAALDH1A1MEN1KMT2A
SCHEMBL1542760 0.79 CYP3A4 (0.55) CYP3A4KDM4EHSD17B10HTTABL1
SCHEMBL1542874 0.78 CYP3A4 (0.51) CYP3A4KDM4EHSD17B10RAB9AHTT
SCHEMBL2128285 0.77 KDM4E (0.49) CYP3A4LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885LMNA 2389/4885ALDH1A1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.